Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...

Special Counsel Says ICON CEO Steve Cutler says trial activity has been “impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.” The company ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and ...

"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...